ArticleLeukemia2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Abstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Guideline
- 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.Leukemia · 2025Guideline
- Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.Blood advances · 2025Trial
- Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.Cancer chemotherapy and pharmacology · 2025Trial
- Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.Clinical pharmacokinetics · 2024Trial
- Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.Leukemia · 2026Article
- Intrinsic cellular resistance to BCR::ABL1 inhibitors.Haematologica · 2026Review
- Article
- Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.Haematologica · 2026Review
- Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1.Genome medicine · 2026Article
- Article
- Reconsidering dualTranslational cancer research · 2026Article
- Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants.Clinical pharmacokinetics · 2026Article
- Asciminib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Case Series and Review of Emerging Evidence.Hematology reports · 2026Article
- FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Cell reports. Medicine · 2026Article
- Vascular Toxicities of Cancer Therapies: 2025 Update.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Ponatinib for CML patients in routine clinical practice: the PONDEROSA study.Annals of hematology · 2026Observational
- Targeted nanoparticle-mediated Co-delivery of IFITM3 KO and ponatinib reverses TKI resistance in chronic myeloid leukemia.Frontiers in pharmacology · 2026Article
- The silent players: AtypicalOncology reports · 2025Review
- Therapeutic positioning of asciminib in chronic myeloid leukemia patients previously treated with multiple tyrosine kinase inhibitors in Qatar.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Jorge E CortesGeorgia Cancer Center at Augusta University, Augusta, GA, USA. Jorge.Cortes@Augusta.edu.ORCID 0000-0002-8636-1071
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9140-0610
Dong-Wook KimUijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, South Korea.
Timothy P HughesSouth Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia.ORCID 0000-0002-0910-3730
Gabriel EtienneDepartment of Hematology, Institut Bergonié, Bordeaux, France.
Michael J MauroMyeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2251-4032
Andreas HochhausHematology/Oncology, Universitätsklinikum Jena, Jena, Germany.ORCID 0000-0003-0626-0834
Fabian LangDepartment of Medicine, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany.
Michael C HeinrichPortland VA Health Care System and OHSU Department of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, Portland, OR, USA.ORCID 0000-0003-3790-0478
Massimo BrecciaDepartment of Translational and Precision Medicine-Az., Policlinico Umberto I-Sapienza University, Rome, Italy.ORCID 0000-0003-1163-6162
Michael DeiningerVersiti Blood Research Institute, Milwaukee, WI, USA.ORCID 0000-0002-2987-1331
Yeow Tee GohDepartment of Haematology, Singapore General Hospital, Bukit Merah, Singapore.ORCID 0000-0002-7069-0997
Jeroen J W M JanssenRadboud University Medical Center, Nijmegen, The Netherlands.
Moshe TalpazDivision of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Valle Gomez Garcia de SoriaHospital Universitario La Princesa, Madrid, Spain.
Philipp le CoutreDepartment of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Daniel J DeAngeloDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-7865-2306
Andrea DamonNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Silvia CacciatoreNovartis Pharma AG, Basel, Switzerland.
Fotis PolydorosNovartis Pharma AG, Basel, Switzerland.
Nithya AgrawalNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0003-4279-8324
Delphine ReaDepartment of Hématologie, Hôpital Saint-Louis, Paris, France.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
Asciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1
Indexed as
Fusion Proteins, bcr-ablLeukemia, Myeloid, Chronic-PhaseMutationProtein Kinase InhibitorsAdultAgedAged, 80 and overAntineoplastic AgentsDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansMaleMiddle AgedNiacinamidePyrazolesAntineoplastic AgentsasciminibFusion Proteins, bcr-ablNiacinamideProtein Kinase InhibitorsPyrazolesTyrosine Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.